Edgewise Therapeutics
Marilyn Mok serves as the Associate Director of DMPK at Edgewise Therapeutics. Prior to this role, Marilyn Mok completed a Clinical Pharmacology Fellowship at UCSF and also worked as a Visiting Scientist at Genentech. This professional trajectory reflects a strong background in drug metabolism and pharmacokinetics, contributing to expertise in the pharmaceutical industry.
This person is not in any teams
This person is not in any offices
Edgewise Therapeutics
1 followers
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it’s Series B financing round which will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. The company’s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.